AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
AbbVie (NYSE: ABBV) has announced the 2024-2025 recipients of its Immunology Scholarship, supporting 45 U.S. students living with chronic immune-mediated diseases. The scholarship, established in 2016, has benefited over 400 undergraduate and graduate students to date. Recipients are equally split among dermatology, gastroenterology, and rheumatology therapeutic areas.
The initiative aims to address the lower graduation rates among young adults with childhood-onset chronic illnesses by providing financial support and empowerment. Applicants are selected based on academic excellence, community leadership, essay submissions, and recommendation letters. The scholarship is open to students pursuing associate, bachelor's, master's, or doctorate degrees who are living with immune-mediated conditions.
AbbVie (NYSE: ABBV) ha annunciato i destinatari del Programma di Borse di Studio in Immunologia per il biennio 2024-2025, supportando 45 studenti statunitensi che vivono con malattie croniche mediate dal sistema immunitario. Il programma di borse, istituito nel 2016, ha beneficiato fino ad oggi oltre 400 studenti universitari e post-laurea. I destinatari sono equamente suddivisi tra le aree terapeutiche di dermatologia, gastroenterologia e reumatologia.
L'iniziativa mira ad affrontare i tassi di laurea più bassi tra i giovani adulti con malattie croniche insorte in infanzia, fornendo supporto finanziario e opportunità di crescita. I candidati vengono selezionati in base a eccellenza accademica, leadership comunitaria, sottomissioni di saggi e lettere di raccomandazione. La borsa è aperta a studenti che perseguono diplomi associati, lauree triennali, master o dottorati e che vivono con condizioni mediate dal sistema immunitario.
AbbVie (NYSE: ABBV) ha anunciado a los beneficiarios de la Beca en Inmunología para 2024-2025, apoyando a 45 estudiantes estadounidenses que viven con enfermedades crónicas mediadas por el sistema inmunitario. La beca, establecida en 2016, ha beneficiado a más de 400 estudiantes de pregrado y posgrado hasta la fecha. Los beneficiarios se distribuyen equitativamente entre las áreas terapéuticas de dermatología, gastroenterología y reumatología.
La iniciativa tiene como objetivo abordar las tasas de graduación más bajas entre los jóvenes adultos con enfermedades crónicas de inicio infantil, proporcionando apoyo financiero y empoderamiento. Los solicitantes son seleccionados en función de la excelencia académica, el liderazgo comunitario, las presentaciones de ensayos y las cartas de recomendación. La beca está abierta a estudiantes que persigan títulos asociados, de licenciatura, de máster o de doctorado y que vivan con condiciones mediadas por el sistema inmunitario.
AbbVie (NYSE: ABBV)는 만성 면역 매개 질환을 앓고 있는 45명의 미국 학생을 지원하는 면역학 장학금의 2024-2025년도 수혜자를 발표했습니다. 2016년에 설립된 이 장학금은 현재까지 400명 이상의 학부 및 대학원생에게 혜택을 주었습니다. 수혜자는 피부과, 위장병학 및 류umatology 분야에 고르게 분포되어 있습니다.
이 이니셔티브는 어린 시절 시작된 만성 질환을 가진 젊은 성인들 사이에서 낮은 졸업률 문제를 해결하기 위해 재정 지원과 권한 부여를 목표로 하고 있습니다. 응모자는 학업 우수성, 지역 사회 리더십, 에세이 제출 및 추천서를 기반으로 선발됩니다. 이 장학금은 면역 매개 질환을 앓고 있는 학생들이 준학사, 학사, 석사 또는 박사 학위를 추구하는 데 열려 있습니다.
AbbVie (NYSE: ABBV) a annoncé les bénéficiaires de sa Bourse en Immunologie pour 2024-2025, soutenant 45 étudiants américains vivant avec des maladies chroniques médiées par le système immunitaire. La bourse, créée en 2016, a bénéficié à plus de 400 étudiants de premier cycle et de cycles supérieurs à ce jour. Les bénéficiaires sont répartis de manière égale entre les domaines thérapeutiques de dermatologie, gastro-entérologie et rhumatologie.
L'initiative vise à remédier aux taux de diplômes plus bas chez les jeunes adultes souffrant de maladies chroniques débutant dans l'enfance, en fournissant un soutien financier et une empowerment. Les candidats sont sélectionnés en fonction de l'excellence académique, du leadership communautaire, des soumissions d'essais et des lettres de recommandation. La bourse est ouverte aux étudiants poursuivant un diplôme associé, de bachelor, de master ou de doctorat et vivant avec des conditions médiées par le système immunitaire.
AbbVie (NYSE: ABBV) hat die Stipendiatinnen und Stipendiaten der Immunologie-Stipendium für 2024-2025 bekannt gegeben, die 45 US-Studierende unterstützt, die an chronisch immunvermittelten Krankheiten leiden. Das im Jahr 2016 gegründete Stipendium hat bis heute mehr als 400 Studierenden auf Bachelor- und Masterebene zugutegekommen. Die Stipendiatinnen und Stipendiaten sind gleichmäßig auf die therapeutischen Bereiche Dermatologie, Gastroenterologie und Rheumatologie verteilt.
Die Initiative zielt darauf ab, die niedrigeren Abschlussquoten unter jungen Erwachsenen mit chronischen Erkrankungen, die im Kindesalter beginnen, zu beheben, indem sie finanzielle Unterstützung und Ermächtigung bereitstellt. Die Bewerber werden auf der Grundlage von akademischen Leistungen, gesellschaftlicher Führung, eingereichten Aufsätzen und Empfehlungsschreiben ausgewählt. Das Stipendium steht Studierenden offen, die einen Associate-, Bachelor-, Master- oder Doktortitel anstreben und die an immunvermittelten Erkrankungen leiden.
- Demonstrates AbbVie's commitment to supporting patients beyond medication
- Potential for positive brand image and customer loyalty in immunology sector
- Long-term investment in future healthcare professionals and researchers
- None.
- More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016
Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9253951-abbvie-immunology-scholarship-2024-2025-recipients/
Due to the constraints of living with chronic illness, research finds that young adults with childhood-onset chronic illness have statistically lower rates of high school and college graduation.1 To honor the determination of these students, the AbbVie Immunology Scholarship strives to ease the financial burden and empower students to achieve their personal and academic aspirations.
"AbbVie is deeply committed to caring for the whole patient in immunology," said Jérôme Bouyer, senior vice president and president of Immunology at AbbVie, "We are honored to support students as they pursue their academic journeys and strive toward a life beyond the constraints of their immune-mediated conditions."
AbbVie awarded scholarships to 45 recipients split equally among dermatology, gastroenterology and rheumatology therapeutic areas. Qualified applicants were selected based on academic excellence, community leadership, essay submission and recommendation letters. By investing in their education, AbbVie intends to promote resilience and inspire hope for a future beyond their disease.
"Receiving the AbbVie Immunology Scholarship is more than just financial support; it is a profound validation of my dedication to achieving my personal and professional goals despite the daily battle with an inflammatory disease," said LaWanda McCraney, 2024-2025 scholarship recipient and PhD candidate at Adler University. "This scholarship is a testament to the potential impact of my work and the importance of perseverance in the face of challenges."
Students living with immune-mediated conditions across dermatology, gastroenterology and rheumatology seeking an associate, bachelor's, master's or doctorate degree are eligible to apply for the AbbVie Immunology Scholarship. Those interested in applying for the 2025-2026 scholarship period, can sign up here to be notified when the application period opens.
Interested students can explore eligibility criteria and apply on the newly relaunched website, www.AbbVieImmunologyScholarship.com.
About the AbbVie Immunology Scholarship
The AbbVie Immunology Scholarship provides financial support to exceptional students living with inflammatory diseases and pursuing higher education in
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
- Maslow, G. R., Haydon, A., McRee, A.-L., Ford, C. A., & Halpern, C. T. (2011). "Growing Up With a Chronic Illness: Social Success, Educational/Vocational Distress". Journal of Adolescent Health, 49(2), 206–212. https://doi.org/10.1016/j.jadohealth.2010.12.001
US-IMM-240094
View original content:https://www.prnewswire.com/news-releases/abbvie-awards-scholarships-to-45-us-students-living-with-chronic-immune-mediated-diseases-302230956.html
SOURCE AbbVie
FAQ
How many students received the AbbVie Immunology Scholarship for 2024-2025?
What medical conditions are covered by the AbbVie Immunology Scholarship?
When was the AbbVie Immunology Scholarship program established?
How many students has the AbbVie Immunology Scholarship helped since its inception?
